ASTRA ZENECA
ZD6474 Trial 62 HNSCC
AN OPEN LABEL, PHASE I STUDY TO ASSESS THE MAXIMUM TOLERATED DOSE OF ZD6474 (ZACTIMATM) GIVEN CONCOMITANTLY WITH RADIATION THERAPY OR CONCOMITANTLY WITH WEEKLY CISPLATIN CHEMOTHERAPY AND RADIATION THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, UNRESECTED, STAGE III-IV HEAD AND NECK SQUAMOUS CELL CARCINOMA
ZD6474 Trial 62 HNSCC
AN OPEN LABEL, PHASE I STUDY TO ASSESS THE MAXIMUM TOLERATED DOSE OF ZD6474 (ZACTIMATM) GIVEN CONCOMITANTLY WITH RADIATION THERAPY OR CONCOMITANTLY WITH WEEKLY CISPLATIN CHEMOTHERAPY AND RADIATION THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, UNRESECTED, STAGE III-IV HEAD AND NECK SQUAMOUS CELL CARCINOMA
Protocol Participation Information
- Credentialing
- ATC IMRT Benchmark
- IMRT Facility Questionnaire
- Dry Run Guidelines rev. 10/20/2006
- How to Participate
- Data Items to Submit to ITC
- Digital Data Submission Procedures
- Digital Data Submission Information Form (formerly T2 form)
- Submission Check list
- ATC Compliant Treatment Planning Systems
- QA Guidelines (IMRT)
- Structure Names
- Neck Node Atlas
- Protocol Text (PDF) (9/14/06)
Back to protocols
